{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:09:33Z","timestamp":1785186573207,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lasers Med Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>It has been recently established that laser treatment can be combined with topical or intralesional medications to enhance the delivery of drugs and improve overall results in a variety of different dermatological disorders. The aim of this review is to evaluate the use of laser and energy-assisted drug delivery (LEADD) for the treatment of alopecia with a specific focus on ablative fractional lasers (AFL), non-ablative fractional lasers (NAFL), and radiofrequency microneedling (RFMN). A comprehensive PubMed search was performed in December 2022 for \u201claser-assisted drug delivery\u201d as well as \u201claser\u201d and \u201calopecia.\u201d The evidence regarding LEADD for alopecia treatment is limited to two specific alopecia subtypes: alopecia areata (AA) and androgenetic alopecia (AGA)\/pattern hair loss (PHL). LEADD with minoxidil and platelet-rich plasma (PRP) were evaluated for efficacy in both treatments of AA and AGA. LEADD with topical corticosteroids and intralesional methotrexate were studied for the treatment of AA, while LEADD with growth factors and stem cells were studied for the treatment of AGA. Multiple RCTs evaluated LEADD for topical corticosteroids with ablative fractional lasers for the treatment of AA. There is evidence in the literature that supports the use of topical minoxidil in combination with all devices for the treatment of AGA\/PHL. All the reviewed studies show a positive treatment effect with LADD; however, some trials did not find LEADD to be superior to monotherapy or microneedling-assisted drug delivery. LEADD is a rapidly emerging treatment modality for the treatment of AGA and AA.<\/jats:p>","DOI":"10.1007\/s10103-024-04015-0","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:02:58Z","timestamp":1708502578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The role of laser and energy-assisted drug delivery in the treatment of alopecia"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-153X","authenticated-orcid":false,"given":"Eliza","family":"Balazic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahava","family":"Muskat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Kost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kseniya","family":"Kobets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"10","key":"4015_CR1","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.ad.2018.07.008","volume":"109","author":"A Alegre-S\u00e1nchez","year":"2018","unstructured":"Alegre-S\u00e1nchez A, Jim\u00e9nez-G\u00f3mez N, Boixeda P (2018) Laser-assisted drug delivery. Actas Dermosifiliogr (Engl Ed) 109(10):858\u2013867","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"1","key":"4015_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"4","key":"4015_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/jocd.12883","volume":"18","author":"W Wang","year":"2019","unstructured":"Wang W, Gegentana G, Tonglaga T, Bagenna B, Li Y (2019) Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. J Cosmet Dermatol. 18(4):1009\u20131013","journal-title":"J Cosmet Dermatol."},{"issue":"1","key":"4015_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.15171\/jlms.2020.06","volume":"11","author":"M Salah","year":"2020","unstructured":"Salah M, Samy N, Fawzy MM, Farrag AR, Shehata H, Hany A (2020) The effect of the fractional carbon dioxide laser on improving minoxidil delivery for the treatment of androgenetic alopecia. J Lasers Med Sci 11(1):29\u201336","journal-title":"J Lasers Med Sci"},{"issue":"9","key":"4015_CR5","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s10103-019-02783-8","volume":"34","author":"P Suchonwanit","year":"2019","unstructured":"Suchonwanit P, Rojhirunsakool S, Khunkhet S (2019) A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Lasers Med Sci 34(9):1857\u20131864","journal-title":"Lasers Med Sci"},{"issue":"7","key":"4015_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/ced.13551","volume":"43","author":"AJ Yu","year":"2018","unstructured":"Yu AJ, Luo YJ, Xu XG, Bao LL, Tian T, Li ZX et al (2018) A pilot split-scalp study of combined fractional radiofrequency microneedling and 5% topical minoxidil in treating male pattern hair loss. Clin Exp Dermatol 43(7):775\u2013781","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"4015_CR7","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.36849\/JDD.6750","volume":"21","author":"N Haddad","year":"2022","unstructured":"Haddad N, Arruda S, Sadick N (2022) Evaluating the efficacy of platelet rich plasma and 1550 nm fractional laser in combination and alone for the management of androgenetic alopecia. J Drugs Dermatol 21(11):1166\u20131169","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"4015_CR8","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jocd.14370","volume":"21","author":"D Day","year":"2022","unstructured":"Day D, McCarthy M, Talaber I (2022) Non-ablative Er:YAG laser is an effective tool in the treatment arsenal of androgenetic alopecia. J Cosmet Dermatol 21(5):2056\u20132063","journal-title":"J Cosmet Dermatol"},{"issue":"4","key":"4015_CR9","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s10103-021-03496-7","volume":"37","author":"S Hanthavichai","year":"2022","unstructured":"Hanthavichai S, Archavarungson N, Wongsuk T (2022) A study to assess the efficacy of fractional carbon dioxide laser with topical platelet-rich plasma in the treatment of androgenetic alopecia. Lasers Med Sci 37(4):2279\u20132286","journal-title":"Lasers Med Sci"},{"issue":"4","key":"4015_CR10","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1204a196","volume":"12","author":"KF El Mulla","year":"2022","unstructured":"El Mulla KF, Elmorsy EH, Halwag DI, Hassan EM (2022) Transepidermal delivery of triamcinolone acetonide or platelet rich plasma using either fractional carbon dioxide laser or micro-needling in treatment of alopecia areata. Dermatol Pract Concept 12(4):e2022196","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"4015_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/14764172.2014.967778","volume":"17","author":"MCA Issa","year":"2015","unstructured":"Issa MCA, Pires M, Silveira P, Xavier de Brito E, Sasajima C (2015) Transepidermal drug delivery: a new treatment option for areata alopecia? J Cosmet Laser Ther. 17(1):37\u201340","journal-title":"J Cosmet Laser Ther."},{"issue":"4","key":"4015_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4103\/JCAS.JCAS_96_18","volume":"11","author":"I Majid","year":"2018","unstructured":"Majid I, Jeelani S, Imran S (2018) Fractional carbon dioxide laser in combination with topical corticosteroid application in resistant alopecia areata: a case series. J Cutan Aesthet Surg 11(4):217\u2013221","journal-title":"J Cutan Aesthet Surg"},{"issue":"12","key":"4015_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15913","volume":"35","author":"MM Omar","year":"2022","unstructured":"Omar MM, Obaid ZM, Sayedahmed OME (2022) Comparative study between topical application of triamcinolone acetonide after fractional carbon dioxide laser versus microneedling in the treatment of resistant alopecia areata. Dermatol Ther 35(12):e15913","journal-title":"Dermatol Ther"},{"issue":"7","key":"4015_CR14","volume":"35","author":"FAE AbdElKawy","year":"2022","unstructured":"Abd ElKawy FAE, Aly SHM, Ibrahim SMA (2022) Fractional CO2 laser versus microneedling as a transepidermal drug delivery system for the treatment of alopecia areata: a clinical dermoscopic evaluation. Dermatol Ther 35(7):e15553","journal-title":"Dermatol Ther"},{"key":"4015_CR15","doi-asserted-by":"publisher","unstructured":"Shokeir HA, Yousry A, Ibrahim SMA (2022) Comparative study between topical steroid alone versus combined fractional Erbium:YAG laser with topical steroid in treatment of alopecia areata. Arch Dermatol Res 315(2):241\u2013247. https:\/\/doi.org\/10.1007\/s00403-022-02417-0","DOI":"10.1007\/s00403-022-02417-0"},{"key":"4015_CR16","doi-asserted-by":"publisher","unstructured":"Halim DA, Nayer M, El-Samanoudy SI, Raheem HMA, Ragab N (2022) Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study. Arch Dermatol Res\u00a0315(3):505\u2013511. https:\/\/doi.org\/10.1007\/s00403-022-02393-5","DOI":"10.1007\/s00403-022-02393-5"},{"issue":"6","key":"4015_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1159\/000524672","volume":"8","author":"A Rodr\u00edguez-Villa Lario","year":"2022","unstructured":"Rodr\u00edguez-Villa Lario A, Aguado-Garc\u00eda \u00c1, Andr\u00e9s-Lencina JJ, Corredera C, Garc\u00eda-Legaz Mart\u00ednez M, Alonso de Celada RM et al (2022) Successful response to a combination of intralesional methotrexate and fractional CO2 laser in refractory alopecia areata: case report. Skin Appendage Disord. 8(6):486\u201391","journal-title":"Skin Appendage Disord."},{"issue":"8","key":"4015_CR18","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s10103-017-2232-8","volume":"32","author":"Y Huang","year":"2017","unstructured":"Huang Y, Zhuo F, Li L (2017) Enhancing hair growth in male androgenetic alopecia by a combination of fractional CO2 laser therapy and hair growth factors. Lasers Med Sci 32(8):1711\u20131718","journal-title":"Lasers Med Sci"},{"issue":"4","key":"4015_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10103-018-2437-5","volume":"33","author":"SB Cho","year":"2018","unstructured":"Cho SB, Goo BL, Zheng Z, Yoo KH, Kang JS, Kim H (2018) Therapeutic efficacy and safety of a 1927-nm fractionated thulium laser on pattern hair loss: an evaluator-blinded, split-scalp study. Lasers Med Sci 33(4):851\u2013859","journal-title":"Lasers Med Sci"},{"issue":"12","key":"4015_CR20","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1097\/DSS.0000000000002518","volume":"46","author":"YI Lee","year":"2020","unstructured":"Lee YI, Kim J, Kim J, Park S, Lee JH (2020) The effect of conditioned media from human adipocyte-derived mesenchymal stem cells on androgenetic alopecia after nonablative fractional laser treatment. Dermatol Surg 46(12):1698\u20131704","journal-title":"Dermatol Surg"},{"issue":"8","key":"4015_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/DSS.0000000000000556","volume":"42","author":"LA Zaleski-Larsen","year":"2016","unstructured":"Zaleski-Larsen LA, Fabi SG (2016) Laser-assisted drug delivery. Dermatol Surg 42(8):919\u2013931","journal-title":"Dermatol Surg"},{"issue":"153","key":"4015_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.addr.2019.10.003","volume":"1","author":"E Wenande","year":"2020","unstructured":"Wenande E, Anderson RR, Haedersdal M (2020) Fundamentals of fractional laser-assisted drug delivery: an in-depth guide to experimental methodology and data interpretation. Adv Drug Deliv Rev 1(153):169\u2013184","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"4015_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/lsm.22666","volume":"49","author":"DM DeBruler","year":"2017","unstructured":"DeBruler DM, Blackstone BN, Baumann ME, McFarland KL, Wulff BC, Wilgus TA et al (2017) Inflammatory responses, matrix remodeling, and re-epithelialization after fractional CO2 laser treatment of scars. Lasers Surg Med 49(7):675\u2013685","journal-title":"Lasers Surg Med"}],"container-title":["Lasers in Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10103-024-04015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10103-024-04015-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10103-024-04015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T15:45:57Z","timestamp":1738338357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10103-024-04015-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4015"],"URL":"https:\/\/doi.org\/10.1007\/s10103-024-04015-0","relation":{},"ISSN":["1435-604X"],"issn-type":[{"value":"1435-604X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Related to the subject of this manuscript, in the past 2\u00a0years, Dr Cohen has done clinical research and\/or consulting for Sciton and Acclaro (laser) (Palo Alto, CA), InMode (RF) (Irvine, CA), and Eclipse\/ Crown (microneedling) (The Colony, TX). The other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}